Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for Eltrombopag

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 05, 2026 · 8 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Eltrombopag, ATC B02BX05

62/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

62 / 100

Złożoność

48 / 100

Czynniki ryzyka

Submission is only valid if the chosen format requirements are met: handwritten paper originals in duplicate or electro...

Participation is restricted to pharmaceutical companies, and suitability must be demonstrated by a signed declaration o...

Submission deadline in 8 days

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Non-exclusive rebate agreements for the active substance Eltrombopag (ATC B02BX05).
  • Supply contract for pharmaceutical products.
Pokaż pełne podsumowanie

This is an open-house pharmaceutical supply arrangement for Eltrombopag (ATC B02BX05) offered by AOK Bayern to all interested pharmaceutical companies that meet the stated eligibility requirement. It is not a competitive award procedure in the usual sense: no selection among bidders, identical non-negotiable contract terms, and no explicit award criteria. Contracting is possible throughout the term, with the latest contract conclusion date stated as 2026-09-05. Submission is possible electronically with a qualified electronic signature via DTVP or in paper form in duplicate originals.

Ryzyka

Submission is only valid if the chosen format requirements are met: handwritten paper originals in duplicate or electro...

Participation is restricted to pharmaceutical companies, and suitability must be demonstrated by a signed declaration o...

Submission deadline in 8 days

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • The contract and the annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for Eltrombopag

Single lot for non-exclusive open-house rebate agreements for the medicinal product Eltrombopag, ATC B02BX05. Scope is pharmaceutical supplies in Germany (place of performance: DEU, DE212). The lot is described as an open-house model with identical, non-individually negotiated contract terms.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Oct 2024 - Oct 2026

Kategoria

Pharmaceutical products

Termin

Deadline Sep 05, 2026

Szczegóły zamówienia

Data publikacji
16 Sep 2024
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
558406-2024

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30